Showing results (91-100 of 114) with videos related to

Sort By:
Pageof 12
Human Vaccines & Immunotherapeutics|October 29, 2013
Safety of an Escherichia coli-expressed bivalent human papillomavirus (types 16 and 18) L1 virus-like particle vaccine: an open-label phase I clinical trialYue-Mei Hu, Shou-Jie Huang, Kai Chu, et al.
The Lancet. Infectious Diseases|November 20, 2020
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trialYanjun Zhang, Gang Zeng, Hongxing Pan, et al.
Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)|September 28, 2021
Real-Time Mobile Teleophthalmology for the Detection of Eye Disease in Minorities and Low Socioeconomics At-Risk PopulationsLama A Al-Aswad, Cansu Yuksel Elgin, Vipul Patel, et al.
Phytotherapy Research : PTR|April 12, 2023
The effect of Andrographis paniculata water extract on palliative management of metastatic esophageal squamous cell carcinoma-A phase II clinical trialPhilip Wai-Yan Chiu, Grace Gar-Lee Yue, Man Kit Cheung, et al.
The Lancet. Global Health|December 27, 2016
Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trialJing-Xin Li, Li-Hua Hou, Fan-Yue Meng, et al.
Plos One|June 5, 2012
Retrospective study of the incidence of HFMD and seroepidemiology of antibodies against EV71 and CoxA16 in prenatal women and their infantsFeng-Cai Zhu, Zheng-Lun Liang, Fan-Yue Meng, et al.
Chinese Medical Journal|April 30, 2021
Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trialsHong-Xing Pan, Jian-Kai Liu, Bao-Ying Huang, et al.
Vaccine|June 24, 2015
Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trialTing Wu, Yue-Mei Hu, Juan Li, et al.
Lancet (London, England)|March 31, 2015
Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trialFeng-Cai Zhu, Li-Hua Hou, Jing-Xin Li, et al.
Nature Communications|December 18, 2023
Autophagy of OTUD5 destabilizes GPX4 to confer ferroptosis-dependent kidney injuryLi-Kai Chu, Xu Cao, Lin Wan, et al.
Pageof 12